drugset / Trial / NCT00237848
D-Serine for Enhancing Cognitive Retraining for the Treatment of Schizophrenia
Phase 3
Completed
72 enrolled
Yale University
Donaghue Foundation · collabStanley Medical Research Institute · collabUS Department of Veterans Affairs · collabVA Office of Research and Development · collab
RandomizedParallel-groupDouble-blindTreatment
Summary
This study will examine the effectiveness of D-serine in increasing and sustaining the benefits of cognitive retraining in people with schizophrenia.
Timeline
- Start
- 2005-02
- Primary completion
- —
- Completion
- —
Publications
- Background Tsai GE, Yang P, Chung LC, Tsai IC, Tsai CW, Coyle JT. D-serine added to clozapine for the treatment of schizophrenia. Am J Psychiatry. 1999 Nov;156(11):1822-5. doi: 10.1176/ajp.156.11.1822.
- Background Tsai G, Yang P, Chung LC, Lange N, Coyle JT. D-serine added to antipsychotics for the treatment of schizophrenia. Biol Psychiatry. 1998 Dec 1;44(11):1081-9. doi: 10.1016/s0006-3223(98)00279-0.
- Background Heresco-Levy U, Javitt DC, Ebstein R, Vass A, Lichtenberg P, Bar G, Catinari S, Ermilov M. D-serine efficacy as add-on pharmacotherapy to risperidone and olanzapine for treatment-refractory schizophrenia. Biol Psychiatry. 2005 Mar 15;57(6):577-85. doi: 10.1016/j.biopsych.2004.12.037.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | D-serine | Unknown | 30 mg/kg | — |